Loading market dashboard
Sanara MedTech Inc.
SMTIHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI PR Newswire
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sanara MedTech delivered a strong Q1 2026, with 19% revenue growth, 93%+ gross margins, and its first GAAP profit in years. SMTI's strategic discontinuation of the THP segment has materially improved profitability, allowing management to focus on the high-return Surgical business. Operating margins now exceed 10%, and guidance for 2026 revenue is $116M–$121M, supporting a Buy rating despite the recent 30% stock rally.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0. 04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the first quarter ended March 31, 2026.
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter
LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanara MedTech Inc. ("Sanara" or "the Company") (NASDAQ: SMTI) for violations of the securities laws.
LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanara MedTech Inc. (“Sanara” or “the Company”) (NASDAQ: SMTI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ICON trades at a low double digit multiple of free cash flow, a fraction of its historical average and a price that materially underestimates the strength of their business. Growth and tumult in private credit, data center financing, and AI driven financial engineering products reinforce the necessity of S&P Global's services. Sanara Medtech continues to be an extremely favorable risk reward with increasing evidence of their product's efficacy recently released and a focus on increasing per hospital doctor penetration.
FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its first quarter 2026 financial results on Tuesday, May 12, 2026 before the U.S. financial markets open.
LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sanara MedTech, Inc. , (“ Sanara " or the "Company") ( NASDAQ : SMTI ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Sanara MedTech (NASDAQ: SMTI - Get Free Report) and ICU Medical (NASDAQ: ICUI - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation. Insider and Institutional Ownership 8.1% of Sanara MedTech
Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript
Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.18 per share a year ago.
FORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Quarter 2025 Financial Summary ( 1 ) Net revenue increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024.
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone
